Director, Pulmonary Vascular Disease Program
CVI Program Unit Administrator:
Pulmonary Vascular Disease
CVI Program Unit(s):
Pulmonary Vascular Disease
Cardiovascular Development / Congenital Heart Disease
Lipid / Atherosclerosis / CAD / ACS / Prevention
Myocyte Biology / Heart Failure
Channel Biology / Electrophysiology
Thrombosis / Hemostasis
CVI Research Description:
The focus of my research group is the role of the pulmonary vasculature and right ventricular function in health and disease. We lead or contribute to epidemiologic studies and clinical trials of pulmonary arterial hypertension, idiopathic pulmonary fibrosis, COPD, and lung transplantation.
Specific projects include:
1. A clinical trial of aspirin and simvastatin for pulmonary arterial hypertension (ASA-STAT)
2. The Pulmonary Vascular Complications of Liver Disease (PVCLD) Study Group, which investigates the mechanisms and outcomes of hepatopulmonary syndrome and portopulmonary hypertension.
3. Endothelial dysfunction and the right ventricle in the Multi-Ethnic Study of Atherosclerosis (MESA-RV)
, focused on the determinants of right ventricular function in subjects without clinical cardiovascular disease.
4. Endothelial dysfunction, bio-markers, and lung function in the Multi-Ethnic Study of Atherosclerosis (MESA-Lung), focused on the relationship of lung function with cardiovascular and peripheral vascular function.
5. The Lung Transplant Outcomes Group
, which is examining the role of pulmonary vascular dysfunction in primary graft dysfunction.
Ventetuolo CE, Praestgaard A, Palevsky HI, Klinger JR, Halpern SD, Kawut SM: Sex and hemodynamics in pulmonary arterial hypertension. Eur Respir J 43(2): 523-30, February 2014.
Goncharov DA, Kudryashova TV, Ziai H, Ihida-Stansbury K, DeLisser H, Krymskaya VP, Tuder RM, Kawut SM, Goncharova EA. : mTORC2 coordinates pulmonary artery smooth muscle cell metabolism, proliferation and survival in pulmonary arterial hypertension. Circulation 129(8): 864-74, February 2014.
Whitman I, Patel VV, Soliman EZ, Bluemke DA, Praestgaard A, Jain A, Herrington D, Lima JAC, Kawut SM: Validity of the surface electrocardiogram criteria for right ventricular hypertrophy: The MESA - Right Ventricle Study. JACC(13), 5435, September 2014.
Smith BM, Kawut SM, Bluemke DA, Basner RC, Gomes AS, Hoffman E, Kalhan R, Lima JAC, Liu C-Y, Michos ED, Prince MR, Rabbani L, Rabinowitz D, Shimbo D, Shea S, Barr RG: Pulmonary hyperinflation and left ventricular mass: The Multi-Ethic Study of Atherosclerosis COPD Study. Circulation 127(14): 1503-11, August 2013.
Grau M, Graham Barr R, Lima JA, Hoffman EA, Bluemke DA, Carr JJ, Chahal H, Enright PL, Jain A, Prince MR, Kawut SM: Percent emphysema and right ventricular structure and function: The MESA Lung and MESA-RV Studies. Chest 144(1): 136-44, July 2013.
Fritz J, Blair C, Oudiz R, Dufton C, Olschewski H, Despain D, Gillies H, Kawut SM: Baseline and follow-up six minute walk distance and BNP predict 2-year mortalilty in pulmonary arterial hypertension. Chest 143(2): 315-23, February 2013.
Kawut SM, Barr RG, Lima JA, Praestgaard A, Johnson WC, Chahal H, Ogunyankin KO, Bristow MR, Kizer JR, Tandri H, Bluemke DA.
: Right ventricular structure is associated with the risk of heart failure and cardiovascular death: The MESA-Right Ventricle Study. Circulation 126(14): 1681-8, October 2012.
Gabler NB, French B, Strom BL, Liu Z, Palevsky HI, Taichman DB, Kawut
SM, Halpern SD: Race and sex differences in response to endothelin receptor antagonists for pulmonary arterial hypertension. Chest 141(1): 20-6, January 2012.
Gabler NM, French B, Strom BL, Palevsky HI, Taichman DB, Kawut SM, Halpern SD: Validation of 6-minute walk distance as a surrogate end point in pulmonary arterial hypertension trials. Circulation 126(3): 349-56, Jul 2012.
back to top
Last updated: 02/13/2017
The Trustees of the University of Pennsylvania